comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 04:45:57 Page View：319

In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp. — Scott Olson/Getty Images

WASHINGTON — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends.

The negotiated prices won’t take effect until 2026.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How Robert F. Kennedy Jr. distorted vaccine science
Next article： Moonlake's readout produced a cash windfall. Risks remain

leisure time

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

STAT wants to know your pick for a great summer read or listen

AdobeSTATisputtingtogetheralistofbooksandpodcaststhatdealwithhealth,medicine,andthelifesciencesthatw

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

DarronCummings/APInasurprisemove,theFoodandDrugAdministrationhascalledforameetingofoutsideadvisersto

comprehensive

knowledge

leisure time

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug